1. Home
  2. AMAT vs AMGN Comparison

AMAT vs AMGN Comparison

Compare AMAT & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Applied Materials Inc.

AMAT

Applied Materials Inc.

HOLD

Current Price

$356.66

Market Cap

239.4B

Sector

Technology

ML Signal

HOLD

Logo Amgen Inc.

AMGN

Amgen Inc.

HOLD

Current Price

$378.34

Market Cap

202.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMAT
AMGN
Founded
1967
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
239.4B
202.4B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
AMAT
AMGN
Price
$356.66
$378.34
Analyst Decision
Buy
Hold
Analyst Count
28
18
Target Price
$334.57
$345.12
AVG Volume (30 Days)
7.1M
2.7M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
0.52%
2.67%
EPS Growth
0.58
88.23
EPS
2.54
14.23
Revenue
$14,608,000,000.00
$25,424,000,000.00
Revenue This Year
$10.99
$4.88
Revenue Next Year
$19.16
$2.58
P/E Ratio
$138.51
$26.56
Revenue Growth
N/A
8.83
52 Week Low
$123.74
$265.66
52 Week High
$395.95
$391.29

Technical Indicators

Market Signals
Indicator
AMAT
AMGN
Relative Strength Index (RSI) 54.09 58.06
Support Level $161.26 $334.89
Resistance Level $395.95 $385.12
Average True Range (ATR) 13.59 7.88
MACD -2.69 -0.99
Stochastic Oscillator 45.80 56.22

Price Performance

Historical Comparison
AMAT
AMGN

About AMAT Applied Materials Inc.

Applied Materials is the largest semiconductor wafer fabrication equipment manufacturer in the world. It has a broad portfolio spanning nearly every corner of the WFE ecosystem. Applied Materials holds leading market share in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: